Diagnostic evaluation for aCML and identification of opportunities for targeted therapy. If a morphologic diagnosis of aCML is rendered, cytogenetic, FISH, and myeloid mutation panel testing are critical as they can unmask karyotypic or molecular abnormalities that have potential implications for use of targeted therapy approaches. *, The ability to target certain genes is expected to change over time as new therapeutics are developed. ^§, Additional JAK2 rearrangements besides the PCM1-JAK2 fusion may present with morphologic features of aCML. BM, bone marrow; PB, peripheral blood; PCR, polymerase chain reaction.